Gabrielle Lakusta

Gabrielle grew up in the Lower Mainland of B.C. and has lived in Vancouver since 2011. She holds an Associate of Arts Degree from Langara College, and a Bachelors of Arts Major in Journalism from Kwantlen Polytechnic University. Now, she writes for INN focusing on Life Science Investing. Aside from work, Gabrielle enjoys travelling, and enjoying the outdoors—especially when hiking and cycling.

glakusta@resourceinvestingnews.com

Articles

Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine

Auris Medical (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central...

January 23rd, 2019

Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain

XBiotech (NASDAQ: XBIT) announced the successful outcome of its multicenter, open label, confirmatory study using bermekimab to treat patients with...

January 23rd, 2019

Aurora Spine Announces New Patent for Its Minimally Invasive Spinal Implants Allowed by the United States Patent Office

Aurora Spine Corporation (TSXV:ASG) announced today the issuance by the United States Patent and Trademark Office (USPTO) of United States...

January 23rd, 2019

InspireMD Announces Two Successful Live Clinical Case Transmissions Featuring CGuard EPS

InspireMD (NYSE:NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of...

January 23rd, 2019

IntelGenx Provides Update on Phase 2a Montelukast VersaFilm Clinical Trial

IntelGenx (TSXV:IGX,OTCQX:IGXT) a leading oral drug delivery company, provided an update on its Phase 2a study of Montelukast VersaFilm in...

January 23rd, 2019

Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem Cell Therapy

Athersys (NASDAQ:ATHX) announced summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat...

January 23rd, 2019

ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women

ObsEva (NASDAQ:OBSV/SIX:OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise...

January 23rd, 2019